MRTX Mirati Therapeutics Inc.

105.55
-0.16  -0%
Previous Close 105.71
Open 105.98
Price To Book 13.41
Market Cap 3,804,774,255
Shares 36,047,127
Volume 257,088
Short Ratio
Av. Daily Volume 828,168

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 initial data 2H 2019.
Sitravatinib and Nivolumab
Renal cell carcinoma (RCC)
Phase 3 trial to be initiated 2Q 2019
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 1b initial data due 2H 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 1/2 update due 2H 2019.
MRTX849
Solid tumors
Phase 2 initial data 2H 2019.
Sitravatinib
Urothelial Carcinoma (Bladder)

Latest News

  1. Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
  2. How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug
  3. The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
  4. Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
  5. The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
  6. Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
  7. 3 Top Biotech Stocks to Buy Right Now
  8. Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
  9. Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
  10. Mirati Therapeutics Announces Proposed Public Offering of Common Stock
  11. Read This Before You Buy Any New Cancer Drug Stocks
  12. Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
  13. Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options
  14. 3 Under-the-Radar Stocks Trading at All-Time Highs
  15. Mirati Therapeutics, Inc. (NASDAQ:MRTX): Financial Strength Analysis
  16. Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX)
  17. Mirati Therapeutics Could Soar Even Higher
  18. The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache
  19. The 10 Best Stocks for 2019 — So Far
  20. Amgen’s Good News on Lung Cancer Boosted Mirati Therapeutics. Here’s What Wall Street Is Saying.